The Top 75: Palio
So, he's the rare agency prexy who can be taken at his word when he says that, as of late-May, his firm finds itself in the strongest competitive position of its 12-year history. “You've interviewed me enough to know I don't always say stuff like that,” Myers says. “It's not because revenue is up and new and organic business are strong, even though they are. It's because we have a more diversified base of business and because of the strength of our talent.”
Specifically, Myers and chief global creative officer Guy Mastrion tout the investments Palio has made over the last several years in two areas: digital and managed care. By getting a jump on the competition, they believe, the firm established a level of credibility that late entrants to the digital and managed-care games lack.
At the same time, Palio spent much of 2010 reengineering its internal processes to better line up with client needs and expectations. Teams were rebuilt around new-media skills and personnel was quickly added to fill any and all gaps. To that end, last year Palio reported a headcount of 100, give or take a few staffers; this year, the firm sits at 128. To accommodate the growth, it added office space on its campus.
There were other growing pains. “In the spirit of continuing to be transparent with you, it hasn't been easy,” Mastrion says. “Most [Palio staffers] have flocked to the change, but some have been indifferent and some want nothing to do with it.”
Clients responded in kind to the renewed vigor, sometimes to an extent that threw Palio for a loop. “You know how it is: People go from not realizing that electricity can fill these things called light bulbs to ‘we want electricity all the time,'” Myers jokes. “That's how it's been with digital. It went from, ‘Hmm, I'm not sure' to ‘I need it six minutes ago and it better be on an iPad.'”
Palio responded deftly to the demands. The agency picked up 24 accounts over the last year against only two losses (Prometheus' cancer drug Proleukin and a local hospital account). Wins included Gilead Sciences' HIV franchise, oncology and palliative care products from Teva Pharmaceutical (“some people are saying they'll be the largest pharmaceutical company in the world by 2020”) and Epocrates for an EHR system (“they were digital before digital was cool”).
Geographic expansion could come next, but the item atop the to-do list is, basically, staying the course, especially as it pertains to digital. “Next year digital won't be on that list,” Mastrion says. “It'll just be ‘this is just a regular part of what we do.'”